|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Invatec, Inc. |
|---|---|
| Information provided by: | Invatec S.p.A. |
| ClinicalTrials.gov Identifier: | NCT00744523 |
Purpose
The objective of the ARMOUR study is to evaluate the safety and effectiveness of the Mo.Ma proximal flow blockage cerebral protection device for patients at high surgical risk for carotid endarterectomy who undergo carotid artery stenting
| Condition | Intervention |
|---|---|
|
Carotid Artery Disease Stroke Prevention |
Device: Carotid Artery Stenting with cerebral protection with the MO.MA device |
| Study Type: | Interventional |
| Study Design: | Prevention, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | ARMOUR: Proximal Protection With The MO.MA Device During Carotid Stenting |
| Enrollment: | 263 |
| Study Start Date: | September 2007 |
| Study Completion Date: | March 2009 |
| Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1: Experimental
Single arm study in which all patients fulfilling the eligibility criteria will be screened and enrolled to undergo carotid stenting with cerebral protection with the MO.MA proximal flow blockage cerebral protection device
|
Device: Carotid Artery Stenting with cerebral protection with the MO.MA device
MO.MA: a proximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons at its distal portion which can be independently inflated and deflated. A central lumen allows advancement and usage of the interventional devices (PTA balloons and carotid stents). The MO.MA is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA, respectively. Cerebral protection is thus established prior to the initial wire passage through the stenosis and maintained during the entire procedure. The MO.MA provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel.
|
Test Device:
Mo.Ma™ Proximal Flow Blockage Cerebral Protection Device (Mo.Ma). Single size catheter device with a 9F introducer sheath compatible shaft (outer diameter) and a 6F compatible working channel (inner diameter), integrating two compliant balloons intended to achieve endovascular clamping of external carotid arteries (ECA) 3-6 mm in diameter and common carotid arteries (CCA) 5-13 mm in diameter.
Primary Objective:
Evaluate the safety and effectiveness of the Mo.Ma device for cerebral protection in the treatment of internal carotid artery (ICA) stenoses, which may or may not involve the bifurcation of the CCA, in subjects considered to be at high surgical risk for complications during carotid endarterectomy (CEA).
Primary Endpoint:
Major adverse cardiac and cerebrovascular events (MACCE) within 30 days of implantation. MACCE are defined as: any myocardial infarction (MI), stroke, or death through day 30 post-procedure.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
General inclusion criteria
Angiographic inclusion criteria (as determined ≤ 30 days prior to procedure):
Target lesion stenosis (% stenosis = (1-N/D) X 100)1, documented by selective angiography pre-intervention, is 1.1. ≥ 80% stenosis for asymptomatic subjects or
1.2. ≥ 50% stenosis for symptomatic subjects. Symptomatic is defined as carotid stenosis associated with ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral ischemic stroke within 6 months prior to enrollment.
General exclusion criteria
Angiographic exclusion criteria (as determined ≤ 30 days prior to procedure):
Contacts and Locations| United States, New York | |
| University at Buffalo Neurosurgery | |
| Buffalo, New York, United States, 14209 | |
| United States, Ohio | |
| MidWest Cardiology Research Foundation | |
| Columbus, Ohio, United States, 43214 | |
| Principal Investigator: | Gary Ansel, MD | Midwest Cardiology Research Foundation |
| Principal Investigator: | L. Nelson Hopkins, MD | University at Buffalo Neurosurgery |
More Information
| Responsible Party: | Invatec Inc. ( Steven R. Camp ) |
| Study ID Numbers: | P-2850 |
| Study First Received: | August 29, 2008 |
| Last Updated: | April 1, 2009 |
| ClinicalTrials.gov Identifier: | NCT00744523 History of Changes |
| Health Authority: | United States: Food and Drug Administration; Italy: Ministry of Health |
|
carotid artery stenting stroke cerebral protection high surgical risk |
|
Nervous System Diseases Stroke Vascular Diseases Central Nervous System Diseases |
Cardiovascular Diseases Brain Diseases Carotid Artery Diseases Cerebrovascular Disorders |